Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

Core Insights - Syndax Pharmaceuticals Inc. has achieved a significant milestone with the inclusion of its drug Revuforj (revumenib) in the NCCN Clinical Practice Guidelines for Acute Myeloid Leukemia (AML) [1][3] - Revumenib received a Category 2A recommendation for treating relapsed or refractory AML with an NPM1 mutation, based on positive results from the AUGMENT-101 trial [2][3] - The FDA has granted Priority Review for Syndax's supplemental New Drug Application for revumenib, with a target action date set for October 25, 2023 [3] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing cancer therapies [4] - The company is currently positioned in a competitive market, with some analysts suggesting that certain AI stocks may offer greater upside potential compared to Syndax [4]